Bradley Pharmaceuticals Announces Receipt Of Acquisition Bids; Ranbaxy Rumored As Possible Suitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement marks the latest episode in a saga that involves activist investors and a defensive move to take the company private.
You may also be interested in...
Nycomed Strengthens Dermatology Franchise With Bradley Purchase
Swiss firm offers $20 per share for New Jersey specialty pharma in deal valued at around $346 million.
Nycomed Strengthens Dermatology Franchise With Bradley Purchase
Swiss firm offers $20 per share for New Jersey specialty pharma in deal valued at around $346 million.
Ranbaxy Strengthens Ties With Injectables Specialist Zenotech
Expanded investment will help Ranbaxy’s position in the specialty sector, firm says; the two Indian companies have already collaborated on development of a biosimilar.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: